A Phase II Study of Irinotecan and Etoposide as Treatment for Refractory Metastatic Breast Cancer.

ABSTRACT:

Lessons learned

The combination of irinotecan and etoposide showed modest efficacy in terms of response rate in the refractory setting for patients with metastatic breast cancer.The studied dose and schedule of irinotecan and etoposide is very toxic, with >70% grade 3 or 4 treatment-related adverse events.

Background

As single agents, both irinotecan and etoposide have documented activity against breast cancer among patients who have received multiple lines of prior chemotherapy. Irinotecan interacts with topoisomerase I (Topo I) to stabilize its cleavable complex, and etoposide has an analogous interaction with topoisomerase II (Topo II). This stabilization without rapid resealing of the cleavage point results in apoptotic cell death and accounts for the antitumor activity

SUBMITTER: Segar JM 

PROVIDER: S-EPMC6975935 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature